Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.
Xiaoxia CaiQingxia ZhuYun ZengYonghua ZhanXue-Li ChenYonghua ZhanPublished in: International journal of nanomedicine (2019)
Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO2, Mn3O4, and MnOx) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies.
Keyphrases
- ionic liquid
- contrast enhanced
- oxide nanoparticles
- magnetic resonance imaging
- magnetic resonance
- room temperature
- crispr cas
- genome editing
- iron oxide nanoparticles
- diffusion weighted imaging
- computed tomography
- cancer therapy
- high resolution
- early stage
- locally advanced
- stem cells
- radiation therapy
- oxidative stress
- deep learning
- photodynamic therapy
- working memory
- chronic pain
- pain management
- convolutional neural network
- drug delivery
- transition metal
- metal organic framework
- sensitive detection
- machine learning
- liver fibrosis
- mesenchymal stem cells
- mass spectrometry